Oncology Research and Treatment
Journal Abbreviation: Oncol Res Treat
ISSN: 2296-5270
eISSN: 2296-5262
Publisher: Karger Publishers
Publications (241)
High PD-1 levels in T cells are associated with an early relapse in lymphoma patients upon autologous stem cell transplantation (2021)
Richter S, Jacobs B, Böttcher M, Mackensen A, Mougiakakos D, Völkl S
Conference contribution
Impact of immunosuppressive treatment on the bioenergetics of T-cells (2021)
Karl F, Gamali S, Mackensen A, Mougiakakos D
Conference contribution
Assessment of educational and social status of survivors of childhood cancer: Data of a single center late effects clinic (2021)
Hahn B, Schuster S, Metzler M, Mackensen A, Meidenbauer N
Conference contribution
Successful treatment of COVID-19 with convalescent plasma in B-cell depleted patients may promote cellular immunity (2021)
Kremer A, Kremer A, Willam C, Verhagen J, Achenbach S, Van Der Meiden E, Lang V, et al.
Conference contribution
Purification and functional characterization of CD34(+) cells from cryopreserved apheresis products of patients with bone marrow infiltrating malignancies (2021)
Wendland K, Petkovic S, Aigner M, Strobel J, Mackensen A, Müller F
Conference contribution
Beta-HCG elevation as first sign of a malignant somatic transformation of a non-seminomatous germ cell tumor (2021)
Peuser M, Hartmann A, Schmidt D, Mackensen A, Meidenbauer N
Conference contribution
Synergy of simultaneous activation of cell death pathways of unfolded protein response and of protein synthesis inhibition converges at IRE1a-immunotoxins generate a therapeutic window (2021)
Gsottberger F, Meier C, Ammon AM, Petkovic S, Mellenthin L, Krumbholz M, Metzler M, et al.
Conference contribution
Metastatic cervical carcinoma: adenocarcinoma = squamous cell carcinoma? (2021)
Hein A
Conference contribution
Identification of human CD4(+) T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential (2021)
Verhagen J, van der Meijden E, Lang V, Kremer A, Völkl S, Mackensen A, Aigner M, Kremer A
Conference contribution
Enasidenib in IDH-2 mutant AML patients with relapse after allogeneic stem cell transplantation (2021)
Vasova I, Spörl S, Guggenberger V, Berisha M, Rech D, Behzad A, Brandt A, et al.
Conference contribution